Home > PRESCRIPTION > Anxiety & Behavior Modification >

Reconcile (Fluoxetine) 64mg, 30 Chewable Tablets

Reconcile (Fluoxetine) 64mg, 30  Chewable Tablets


 

Sold ONLY to licensed veterinarians and pharmacies. Submit license if not already on file. Fax :: 800-640-3274

Licensed Professional Price: $58.82
Rx:
Copy of License Required [No Prescriptions Please]

Stock Status:In Stock


Product Code: 16344
Qty:

Description
 
New Page 2

RECONCILE (fluoxetine) Chewable Tablets

RECONCILE is a chewable, flavored tablet that contains fluoxetine hydrochloride. RECONCILE chewable tablets are available in 8, 16, 32, and 64 mg tablet strengths for oral administration to dogs. The active ingredient in RECONCILE chewable tablets is fluoxetine hydrochloride, a selective serotonin reuptake inhibitor (SSRI). RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan.

Dosage and Administration:

The recommended dose of RECONCILE chewable tablets is 1-2 mg/kg (0.5-0.9 mg/lb) administered once daily, in conjunction with a behavior modification plan. A typical behavior modification plan consists of the pet owner implementing standard training techniques based on principles such as rewarding appropriate behavior; coming and going in a manner that does not elicit inappropriate responses from the dog; and teaching the dog to be content while alone.

Table 1: Recommended Dose of RECONCILE Chewable Tablets

Dog Weight

No. of Tablets/day

Tablet Strength (mg)

(lb)

(kg)

8.8 - 17.6

4.0 - 8.0

1

8

17.7 - 35.2

8.1 -16.0

1

16

35.3 - 70.4

16.1 - 32.0

1

32

70.5 - 140.8

32.1 - 64.0

1

64

The effectiveness and safety of RECONCILE chewable tablets was demonstrated in a field study in client-owned dogs. At the end of the 8-week study, 73% of dogs treated with RECONCILE chewable tablets showed significant improvement (p=0.010), as compared to behavior modification alone (51%). During the course of therapy, 42% of dogs showed improvement within the first week, which was significantly greater (p=0.005) than with behavior modification alone (18%). The patient's response to therapy should be monitored. If no improvement is noted within 8 weeks, case management should be reevaluated.

The effectiveness and clinical safety of RECONCILE chewable tablets for long-term use (i.e. for more than 8 weeks) has not been evaluated. RECONCILE chewable tablets were evaluated at the recommended label dose for one year in a laboratory safety study in dogs.

Professional judgment should be used in monitoring the patient's response to therapy to determine the need to continue treatment with RECONCILE chewable tablets beyond 8 weeks. To discontinue therapy, it is not necessary to taper or reduce doses because of the long half-life of this product. Continued behavioral modification is recommended to prevent recurrence of the clinical signs.

RECONCILE chewable tablets are readily consumed by dogs or can be administered like other tablet medications, and can be given with or without food.

Professional discretion should be used in determining the need for dose reduction in the event of a possible adverse reaction. Approximately half of patients tolerate a return to the previous dose after 1-2 weeks on a reduced schedule.

If a dose is missed, the next scheduled dose should be administered as prescribed. Do not increase or double the dose.

Contraindications:

RECONCILE chewable tablets are contraindicated for use in dogs with epilepsy or a history of seizures. RECONCILE chewable tablets should not be given concomitantly with drugs that lower the seizure threshold (e.g., phenothiazines such as acepromazine or chlorpromazine).

RECONCILE chewable tablets should not be given in combination with a monoamine oxidase inhibitor (MAOI) [e.g., selegiline hydrochloride (L-deprenyl) or amitraz], or within a minimum of 14 days of discontinuing therapy with an MAOI.

RECONCILE chewable tablets are contraindicated in dogs with a known hypersensitivity to fluoxetine HCl or other SSRIs.

Because fluoxetine and its major metabolite, norfluoxetine, have long half-lives, a 6-week washout interval should be observed following discontinuation of therapy with RECONCILE chewable tablets prior to the administration of any drug that may adversely interact with fluoxetine or norfluoxetine.

Rx Medication Sold Only To Licensed Veterinarians & Pharmacies. Current License Must Be On File Prior To Shipping


Share your knowledge of this product. Be the first to write a review »